8-K: Nektar Therapeutics Reports Second Quarter 2024 Financial Results, Advances Clinical Programs

Nektar Therapeutics announced its second quarter 2024 financial results, highlighting progress in clinical trials and a cash runway extending into the third quarter of 2026.

Summary

• Nektar Therapeutics reported a revenue of $23.5 million for the second quarter of 2024, compared to $20.5 million in the same period of 2023.
• The company's revenue for the first half of 2024 reached $45.1 million, up from $42.1 million in the first half of 2023.
• Total operating costs and expenses for the second quarter of 2024 were $73.3 million, slightly higher than the $71.1 million in the second quarter of 2023.
• Operating costs and expenses for the first half of 2024 decreased to $130.3 million, compared to $227.4 million in the first half of 2023, primarily due to a reduction in restructuring and impairment costs.
• Research and development expenses were $29.7 million in the second quarter of both 2024 and 2023, while for the first half of 2024, R&D expenses were $57.1 million compared to $60.2 million in the first half of 2023.
• General and administrative expenses increased to $20.5 million in the second quarter of 2024 from $17.9 million in the second quarter of 2023.
• The company's net loss for the second quarter of 2024 was $52.4 million, or $0.25 per share, compared to a net loss of $51.1 million, or $0.27 per share, in the second quarter of 2023.
• Nektar's net loss for the first half of 2024 was $89.2 million, or $0.44 per share, compared to a net loss of $188.1 million, or $0.99 per share, in the first half of 2023.
• Excluding non-cash restructuring and real estate impairment charges, the non-GAAP net loss for the second quarter and first half of 2024 were $39.1 million and $74.9 million, respectively.
• Cash and investments in marketable securities were $290.6 million as of June 30, 2024, compared to $329.4 million at the end of 2023.
• Nektar's cash and marketable securities are expected to support operations into the third quarter of 2026.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The company is making good progress in its clinical programs and has a strong cash position, but it is still operating at a loss. The positive clinical trial results and extended cash runway are encouraging, but the ongoing losses and increased G&A expenses temper the overall sentiment.

Positives

• Revenue increased in both the second quarter and first half of 2024 compared to the same periods in 2023.
• Operating costs and expenses decreased significantly in the first half of 2024 compared to the first half of 2023.
• The company has a strong cash position with a runway extending into the third quarter of 2026.
• Clinical trials for rezpegaldesleukin are progressing as planned, with topline data expected in 2025.
• Preclinical data for NKTR-0165 shows promise as a potential first-in-class treatment for autoimmune diseases.
• The NKTR-255 trial showed very promising results in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Negatives

• The company experienced a net loss of $52.4 million in the second quarter of 2024.
• General and administrative expenses increased in both the second quarter and first half of 2024.
• Non-cash restructuring and impairment charges of $13.3 million were incurred in the second quarter of 2024 due to the declining San Francisco commercial real estate market.
• Cash and investments decreased from $329.4 million at the end of 2023 to $290.6 million as of June 30, 2024.

Risks

• The therapeutic potential of rezpegaldesleukin, NKTR-0165, and NKTR-255 is subject to change as research and development continues.
• Clinical trials for rezpegaldesleukin and NKTR-255 are subject to the risk of failure.
• The timing of clinical trials and the availability of clinical data may be delayed.
• The company may not achieve the expected cost savings from restructuring plans.
• Patents may not issue from patent applications, or existing patents may not be enforceable.
• The company is subject to risks related to health epidemics, regulatory delays, patient enrollment, manufacturing challenges, and competitive factors.

Future Outlook

Nektar expects to continue advancing its clinical programs, with topline data for rezpegaldesleukin expected in 2025 and an IND submission for NKTR-0165 also targeted for 2025. The company's cash is expected to support operations into the third quarter of 2026.

Management Comments

• We continue to make excellent progress advancing rezpegaldesleukin in Phase 2 studies in patients with atopic dermatitis and alopecia areata, said Howard W. Robin, President and CEO of Nektar.
• We are particularly pleased that enrollment is on track for topline data in the first half of 2025 for atopic dermatitis and topline data in mid-2025 for alopecia areata.
• For our TNFR2 agonist antibody, NKTR-0165, we are conducting IND-enabling studies with the goal of preparing for an IND submission in the middle of 2025.
• Finally, we remain in a strong financial position with a cash runway extending into the third quarter of 2026.

Industry Context

This announcement reflects the ongoing efforts of biotechnology companies to develop novel treatments for autoimmune and inflammatory diseases. Nektar's focus on immunomodulation and its pipeline of clinical and preclinical candidates align with current trends in the pharmaceutical industry. The positive data from the NKTR-255 trial also highlights the potential of combination therapies in oncology.

Comparison to Industry Standards

• Nektar's revenue growth is modest compared to some larger biotech companies, but its focus on early-stage clinical development is typical for a company of its size.
• The reduction in operating costs is a positive sign, as many biotech companies struggle with high expenses during the development phase.
• The cash runway extending into the third quarter of 2026 is a strong indicator of financial stability, which is crucial for biotech companies with long development timelines.
• The clinical trial results for NKTR-255 are very promising, with a 67% remission-free survival rate at 12 months, which is significantly better than historical controls. This compares favorably to other CAR-T cell therapies in the market.
• The development of NKTR-0165 as a TNFR2 agonist antibody is a novel approach, and its potential as a first-in-class treatment could give Nektar a competitive advantage in the autoimmune disease market. Companies like AbbVie and Amgen are also active in this space, but with different approaches.

Stakeholder Impact

• Shareholders may be encouraged by the progress in clinical trials and the extended cash runway.
• Employees may be reassured by the company's financial stability and ongoing development activities.
• Patients may benefit from the potential development of new treatments for autoimmune and inflammatory diseases.
• Creditors may be confident in the company's ability to meet its financial obligations.

Next Steps

• Nektar will continue to advance the Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata.
• The company will conduct IND-enabling studies for NKTR-0165 with the goal of an IND submission in mid-2025.
• Nektar will present data at upcoming scientific congresses.
• The company will host a conference call to discuss the second quarter 2024 financial results.

Key Dates

Keywords

Nektar Therapeutics, rezpegaldesleukin, NKTR-0165, NKTR-255, atopic dermatitis, alopecia areata, TNFR2 agonist, immunotherapy, clinical trials, biotechnology, financial results